| Colorectal Carcinoma
Opdivo vs Vectibix
Side-by-side clinical, coverage, and cost comparison for colorectal carcinoma.Deep comparison between: Opdivo vs Vectibix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVectibix has a higher rate of injection site reactions vs Opdivo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vectibix but not Opdivo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Opdivo
Vectibix
At A Glance
IV infusion
Every 2 weeks or Every 4 weeks
PD-1 blocking antibody
IV infusion
Every 2 weeks
EGFR antagonist
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Renal Cell Carcinoma
- Hodgkin Disease
- Squamous cell carcinoma of the head and neck
- Urothelial Carcinoma
- Colorectal Carcinoma
- Liver carcinoma
- Squamous cell carcinoma of esophagus
- Stomach Carcinoma
- Gastroesophageal junction cancer
- Adenocarcinoma Of Esophagus
- Colorectal Carcinoma
Dosing
Melanoma Adults and pediatric >=40 kg: 240 mg every 2 weeks or 480 mg every 4 weeks; Pediatric <40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks
Non-Small Cell Lung Carcinoma Neoadjuvant: 360 mg every 3 weeks with platinum-doublet chemotherapy for 3-4 cycles; Adjuvant after neoadjuvant: 480 mg every 4 weeks; Metastatic: 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks; or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks and 2 cycles platinum-doublet chemotherapy; or 240 mg every 2 weeks or 480 mg every 4 weeks
Malignant Pleural Mesothelioma 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks
Renal Cell Carcinoma 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks; or 240 mg every 2 weeks or 480 mg every 4 weeks with cabozantinib 40 mg daily orally; or 240 mg every 2 weeks or 480 mg every 4 weeks
Hodgkin Disease Previously untreated: Adults and pediatric >=40 kg: 240 mg with AVD every 2 weeks for 6 cycles; Pediatric <40 kg: 3 mg/kg with AVD every 2 weeks for 6 cycles; Relapsed or refractory: 240 mg every 2 weeks or 480 mg every 4 weeks
Squamous cell carcinoma of the head and neck 240 mg every 2 weeks or 480 mg every 4 weeks
Urothelial Carcinoma Adjuvant: 240 mg every 2 weeks or 480 mg every 4 weeks; First-line: 360 mg every 3 weeks with cisplatin and gemcitabine for up to 6 cycles, then 240 mg every 2 weeks or 480 mg every 4 weeks; Previously treated: 240 mg every 2 weeks or 480 mg every 4 weeks
Colorectal Carcinoma Adults and pediatric >=40 kg: 240 mg with ipilimumab 1 mg/kg every 3 weeks for maximum 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks; Pediatric <40 kg: 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for maximum 4 doses, then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks
Liver carcinoma 1 mg/kg with ipilimumab 3 mg/kg every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks
Squamous cell carcinoma of esophagus Adjuvant resected: 240 mg every 2 weeks or 480 mg every 4 weeks for 1 year; First-line with chemotherapy: 240 mg every 2 weeks or 480 mg every 4 weeks with fluoropyrimidine- and platinum-containing chemotherapy; First-line with ipilimumab: 3 mg/kg every 2 weeks or 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks; Previously treated: 240 mg every 2 weeks or 480 mg every 4 weeks
Stomach Carcinoma 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks
Gastroesophageal junction cancer 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks
Adenocarcinoma Of Esophagus 360 mg every 3 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 3 weeks or 240 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks
Colorectal Carcinoma (RAS Wild-Type mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) as monotherapy or in combination with FOLFOX.
Colorectal Carcinoma (KRAS G12C-Mutated mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) in combination with sotorasib; administer first sotorasib dose prior to first Vectibix infusion.
Contraindications
—
Adverse Reactions
Most common (>=20%) fatigue, musculoskeletal pain, rash, diarrhea, pruritus, nausea, decreased appetite, cough, dyspnea, constipation, upper respiratory tract infection
Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, myocarditis, neurological toxicities, infusion-related reactions
Most common (>=20%) Rash, acneiform dermatitis, erythema, pruritus, dry skin, paronychia, diarrhea, stomatitis, mucosal inflammation, fatigue, asthenia, nausea, anorexia, hypomagnesemia, hypokalemia, musculoskeletal pain
Serious General physical health deterioration, intestinal obstruction, diarrhea, dehydration, sepsis, cardiac arrest
Postmarketing Skin necrosis, angioedema, bullous mucocutaneous disease, infusion reaction, keratitis, ulcerative keratitis, corneal perforation
Pharmacology
Nivolumab is a PD-1 blocking antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Panitumumab is a fully human IgG2 monoclonal antibody that competitively blocks ligand binding to EGFR, inhibiting receptor autophosphorylation and downstream signaling, thereby inhibiting tumor cell growth and inducing apoptosis; in KRAS G12C-mutated mCRC, combining EGFR blockade with sotorasib overcomes EGFR-mediated resistance to KRAS G12C inhibition.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Opdivo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (0/12)
Vectibix
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Opdivo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vectibix
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Humana
Opdivo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Vectibix
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Opdivo.
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OpdivoView full Opdivo profile
VectibixView full Vectibix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.